SCM
INSY

Schneider Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Schneider Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-181,900
Closed -$1.61M – 59
2017
Q3 		$1.61M Buy
181,900
+61,927
+52% +$639K 0.29% 45
2017
Q2 		$1.52M Buy
119,973
+60,000
+100% +$710K 0.29% 49
2017
Q1 		$630K Buy
59,973
+15,000
+33% +$160K 0.11% 54
2016
Q4 		$414K Buy
+44,973
New +$508K 0.07% 54

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schneider Capital Management's INSY Position: Q4 2017 in Review

Schneider Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 181,900 shares — an estimated $1.61M sold.

Schneider Capital Management first reported a position in INSY in Q4 2016 and held it in 4 quarters. The position peaked at $1.61M in Q3 2017. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • Schneider Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Schneider Capital Management sold 181,900 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $1.61M.
  • Schneider Capital Management first reported a position in Insys Therapeutics, Inc. in Q4 2016 and held it in 4 quarters.
  • Schneider Capital Management's Insys Therapeutics, Inc. position peaked at $1.61M in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on Schneider Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.